JP2016525563A5 - - Google Patents

Download PDF

Info

Publication number
JP2016525563A5
JP2016525563A5 JP2016530548A JP2016530548A JP2016525563A5 JP 2016525563 A5 JP2016525563 A5 JP 2016525563A5 JP 2016530548 A JP2016530548 A JP 2016530548A JP 2016530548 A JP2016530548 A JP 2016530548A JP 2016525563 A5 JP2016525563 A5 JP 2016525563A5
Authority
JP
Japan
Prior art keywords
carbon atoms
alkyl
therapeutic agent
halogen atom
diazepin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016530548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525563A (ja
JP6453877B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/066629 external-priority patent/WO2015014998A1/en
Publication of JP2016525563A publication Critical patent/JP2016525563A/ja
Publication of JP2016525563A5 publication Critical patent/JP2016525563A5/ja
Application granted granted Critical
Publication of JP6453877B2 publication Critical patent/JP6453877B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016530548A 2013-08-01 2014-08-01 チエノトリアゾロジアゼピン化合物を含む医薬製剤 Expired - Fee Related JP6453877B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361861291P 2013-08-01 2013-08-01
US61/861,291 2013-08-01
US201361863118P 2013-08-07 2013-08-07
US61/863,118 2013-08-07
PCT/EP2014/066629 WO2015014998A1 (en) 2013-08-01 2014-08-01 Pharmaceutical formulation containing thienotriazolodiazepine compounds

Publications (3)

Publication Number Publication Date
JP2016525563A JP2016525563A (ja) 2016-08-25
JP2016525563A5 true JP2016525563A5 (enExample) 2017-09-14
JP6453877B2 JP6453877B2 (ja) 2019-01-16

Family

ID=51260882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016530548A Expired - Fee Related JP6453877B2 (ja) 2013-08-01 2014-08-01 チエノトリアゾロジアゼピン化合物を含む医薬製剤

Country Status (6)

Country Link
US (1) US9795612B2 (enExample)
EP (1) EP3027194A1 (enExample)
JP (1) JP6453877B2 (enExample)
KR (1) KR20160036591A (enExample)
CN (1) CN106029077A (enExample)
WO (1) WO2015014998A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016538310A (ja) * 2013-11-27 2016-12-08 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法
WO2015168621A1 (en) * 2014-05-02 2015-11-05 Oncoethix Sa Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds
CN107427524A (zh) * 2014-08-28 2017-12-01 翁科埃斯克斯有限公司 利用包含噻吩并三唑并二氮杂*化合物的药物组合物治疗急性髓细胞白血病或急性淋巴性白血病的方法
WO2016156905A1 (en) * 2015-04-03 2016-10-06 Oncoethix Gmbh Pharmaceutical doses for a bromodomain and extraterminal protein (bet) inhibitor
WO2016176335A1 (en) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Deuterated otx-015
WO2019022784A1 (en) * 2017-07-24 2019-01-31 Acryspharm Llc PHARMACEUTICAL COMPOSITIONS WITH HIGH MEDICATION CHARGE
EP4351560A4 (en) 2021-06-08 2025-06-04 The Regents of the University of California ANTI-CANCER COMPOUNDS

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011111A1 (en) * 1996-09-13 1998-03-19 Yoshitomi Pharmaceutical Industries, Ltd. Thienotriazolodiazepine compounds and medicinal uses thereof
JP4875277B2 (ja) * 2000-06-16 2012-02-15 田辺三菱製薬株式会社 放出pH域及び/又は速度制御組成物
AU2006270187A1 (en) * 2005-07-15 2007-01-25 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant SRC kinase polypeptides
JP2010517510A (ja) * 2007-01-09 2010-05-27 ブリストル−マイヤーズ スクイブ カンパニー 前立腺細胞中のタンパク質チロシンキナーゼおよび/またはタンパク質チロシンキナーゼ経路と相互作用しかつ/またはそれを調節する化合物の活性を予測するためのポリヌクレオチドの同定
CN101910182B (zh) * 2007-12-28 2013-07-17 田边三菱制药株式会社 抗癌剂
RU2016116516A (ru) * 2008-12-08 2018-12-07 Мандифарма Интернэшнл Корпорейшн Лимитед Композиции ингибиторов тирозинкиназных рецепторов белков
WO2011143651A1 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
CN103154246B (zh) 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
WO2012075456A1 (en) * 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
CA2877434A1 (en) * 2012-06-25 2014-01-03 Oncoethix Sa Method of treating lymphoma using thienotriazolodiazepine compounds
WO2014068402A2 (en) * 2012-09-28 2014-05-08 Oncoethix Sa Pharmaceutical formulation containing thienotriazolodiazepine compounds
JP2016538310A (ja) * 2013-11-27 2016-12-08 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法

Similar Documents

Publication Publication Date Title
JP2015531747A5 (enExample)
JP2016529246A5 (enExample)
JP2016538310A5 (enExample)
JP2017517579A5 (enExample)
RU2015101106A (ru) Способ лечения лимфомы, применяя тиенотриазолодиазепиновые соединения
JP2016523270A5 (enExample)
JP2016507581A5 (enExample)
HRP20201985T1 (hr) Piridonski spoj kao c-met inhibitor
RU2015133528A (ru) Замещенные полициклические пиразольные ингибиторы киназной активности и их применение
JP2020517616A5 (enExample)
JP2013540712A5 (enExample)
JP2021501208A5 (enExample)
JP2010241830A5 (enExample)
JP2019512535A5 (enExample)
JP2016501185A5 (enExample)
JP2017529332A5 (enExample)
JP2014518544A5 (enExample)
JP2011527667A5 (enExample)
JP2014514317A5 (enExample)
JP2009511490A5 (enExample)
JP2015509536A5 (enExample)
JP2016531868A5 (enExample)
CN106660974A (zh) 含氨磺酰基的1,2,5‑噁二唑类衍生物、其制备方法及其在医药上的应用
JP2017519727A5 (enExample)
JP2015504091A5 (enExample)